Oseltamivir (Tamiflu)
Is It Right for You?
A complete guide to Oseltamivir (Tamiflu) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Oseltamivir (Tamiflu)?
Oseltamivir phosphate, marketed as Tamiflu, is an oral antiviral agent belonging to the neuraminidase inhibitor class. It is available as capsules (30 mg, 45 mg, 75 mg) and as an oral suspension (6 mg/mL) for children. It is active against both influenza A (including pandemic strains) and influenza B.
Oseltamivir is the most widely used influenza antiviral globally and forms a cornerstone of national pandemic influenza preparedness plans. When initiated within 48 hours of symptom onset in otherwise healthy adults with uncomplicated influenza, it reduces the duration of illness by approximately one day and modestly reduces complication rates. It provides greater and clinically more meaningful benefit in high-risk patient groups — including the elderly, immunocompromised patients, and those with chronic medical conditions — where it significantly reduces hospitalisation and complications.
Oseltamivir is a prescription-only medication in the UK. A clinician must assess whether treatment is clinically appropriate based on symptom duration, risk category, and local influenza surveillance data.
What Conditions Is Oseltamivir Used For?
Oseltamivir is indicated for:
for symptomatic treatment in adults and children when influenza is circulating; most effective when initiated within 48 hours of symptom onset
prevention in individuals who have been in close contact with a confirmed influenza case; recommended particularly for high-risk individuals during active influenza outbreaks
for immunocompromised patients or others at very high risk during influenza season when vaccination is contraindicated or has failed
Oseltamivir reduces the duration and severity of influenza but is not a substitute for annual influenza vaccination, which is the most effective preventive measure. It should not be used routinely in healthy adults with uncomplicated influenza as a convenience medication. It is most appropriately targeted at high-risk patients, severely ill patients, and post-exposure prophylaxis in vulnerable contacts.
How Does Oseltamivir Work?
Oseltamivir is a prodrug. Following oral absorption, it is rapidly hydrolysed by hepatic and intestinal esterases to oseltamivir carboxylate — the active antiviral compound — which exerts its effect through neuraminidase inhibition:
Influenza neuraminidase: The influenza virus surface glycoprotein neuraminidase (NA) plays a critical role in the viral replication cycle. After new viral particles have been assembled within the infected host cell, neuraminidase cleaves the sialic acid linkages that bind newly formed virions to the surface of the infected cell and to each other — releasing them to infect neighbouring cells and spread through the respiratory tract.
Competitive inhibition of neuraminidase: Oseltamivir carboxylate is a competitive, reversible inhibitor of influenza neuraminidase. By binding to the active site of NA and blocking its sialidase activity, oseltamivir prevents the release of newly assembled viral particles from infected cells. Virions aggregate on the cell surface and are unable to spread efficiently to adjacent cells. This limits the extent of infection, reduces viral load, and allows the immune system to contain the infection more effectively — shortening the duration and severity of illness.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Start treatment as early as possible — within 48 hours of symptom onset. The antiviral effect of oseltamivir is dependent on being initiated while viral replication is still active. Treatment started after 48 hours has significantly reduced efficacy in otherwise healthy individuals, though it may still benefit high-risk or hospitalised patients.
Can be taken with or without food. Taking oseltamivir with food reduces the incidence of nausea and vomiting without affecting bioavailability.
Complete the full 5-day course. Do not stop early if you feel better — completing the course reduces the risk of viral resurgence and minimises the risk of antiviral resistance development.
The oral suspension must be shaken before each use. Ensure accurate dosing in children using the supplied measuring device.
For post-exposure prophylaxis, start as soon as possible after exposure — within 48 hours. Prophylaxis does not replace vaccination.
Side Effects of Oseltamivir
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Nausea --- the most commonly reported side effect; typically mild to moderate; taking with food substantially reduces nausea
- Vomiting
- Headache
- Abdominal pain
- Diarrhoea
- Dizziness
- Severe hypersensitivity reactions --- anaphylaxis, angioedema, urticaria, and serious skin reactions (including Stevens-Johnson Syndrome); rare
- Neuropsychiatric events --- confusion, abnormal behaviour, hallucinations, and self-harm, particularly in children and adolescents; a rare but reported association, primarily from post-marketing surveillance in Japan; a causal relationship has not been definitively established but patients and carers should be aware; seek medical attention immediately if neuropsychiatric symptoms develop
- Hepatitis --- rare cases of severe hepatic dysfunction reported
- Renal failure --- rare; monitor in patients with pre-existing renal impairment
Post-marketing surveillance, predominantly from Japan, has reported rare cases of abnormal behaviour, delirium, and self-harm in children and adolescents receiving oseltamivir — though similar events occur in influenza itself, making causality uncertain. Parents and carers should monitor children closely during treatment for any new neurological or behavioural changes and seek immediate medical attention if these occur.
Drug Interactions
Oseltamivir may interact with other medications, including the live attenuated influenza vaccine (LAIV) and probenecid. Always inform your clinician about all medications you are taking.
oseltamivir inhibits viral replication, which may reduce the efficacy of the live attenuated intranasal influenza vaccine; do not administer LAIV within 2 weeks before or 48 hours after oseltamivir treatment.
blocks renal tubular secretion of oseltamivir carboxylate, doubling plasma concentrations; dose reduction of oseltamivir may be required in patients on probenecid; not clinically relevant at standard treatment doses in most patients.
no clinically significant pharmacokinetic interactions with most antivirals at recommended doses.
Important Warnings
Oseltamivir's therapeutic benefit is highly time-dependent. In otherwise healthy adults, starting after 48 hours of symptom onset provides little measurable benefit. If influenza is suspected in a high-risk patient and influenza is known to be circulating locally, early empirical treatment is preferred over waiting for laboratory confirmation.
Rare neuropsychiatric events have been reported in children and adolescents receiving oseltamivir. Parents and carers must be counselled to watch for any unusual behavioural changes, confusion, or self-harming behaviour and to seek immediate medical attention if these occur. It is unclear whether these events are caused by the drug or by influenza itself.
Oseltamivir and its active metabolite are renally excreted. Dose reduction is required in patients with reduced eGFR; standard doses in patients with significant renal impairment can cause drug accumulation and adverse effects.
Oseltamivir must not be given within 2 weeks of receiving the live nasal influenza vaccine (LAIV), as it may prevent the vaccine virus from replicating effectively and reduce immunogenicity. Inactivated injectable flu vaccines are not affected.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Oseltamivir FAQs
In otherwise healthy adults with uncomplicated influenza, oseltamivir reduces illness duration by approximately 17–21 hours when started within 48 hours of symptom onset. This is a modest but genuine benefit. The benefit is considerably more meaningful in high-risk patients — including the elderly, those with chronic medical conditions, and hospitalised patients — where oseltamivir significantly reduces complications, hospital admissions, and mortality.
For healthy adults with mild-to-moderate uncomplicated influenza, starting after 48 hours provides little benefit. However, clinicians may still recommend oseltamivir in high-risk patients (including elderly, immunocompromised, or those with complications) beyond this window, as evidence suggests continued benefit in these groups.
Yes. Post-exposure prophylaxis (taking 75 mg once daily for 10 days after close contact with a confirmed influenza case) is effective in reducing the likelihood of developing influenza, particularly in high-risk individuals during active outbreaks. This is not a substitute for annual vaccination but can provide important protection when vaccination has not been received or may have been insufficient.
No. Oseltamivir is specifically active against influenza A and B viruses via neuraminidase inhibition. It has no activity against SARS-CoV-2 (COVID-19), rhinoviruses, RSV, or other respiratory pathogens.
Oseltamivir is most effective when started early and when the immune system's initial response to influenza is impaired — explaining why it provides greatest clinical benefit in high-risk groups (elderly, immunocompromised, pregnant women) where the consequences of influenza are most severe. In young, healthy adults with robust immune responses, the immune system often controls influenza effectively regardless of antiviral treatment.